Other

University of Texas System

Introgen Therapeutics Inc.

Abner Mhashilkar

Elizabeth A Grimm

Rajagopal Ramesh

Sunil Chada

Wayne A Marasco

Jack A Roth

David B Ring

Sunil D Chada

Tapas Mukhopadhyay

Urban Ramstedt

Bridget Eberhardt

Joyce Lavecchio

Julie Porter-Brooks

Raymond E Meyn

John B Mumm

The present invention is directed to the use of benzimidazole derivatives for the treatment of tumors and in combination with tumor suppressor gene therapy. In a particular embodiment, treatment of p53-positive tumors with benzimidazole derivatives induces p53 expression and increases its half-life, resulting in apoptotic death of the tumor cells. Similarly, in conjunction with p53 gene therapy, benzimidazole derivatives induce p53 expression and accumulation in tumor cells regardless of their p53 status. The combination treatment subsequently elicits apoptosis of the tumor cells.

Antihelminthic drugs as a treatment for hyperproliferative diseases

A humanized antibody framework motif is described. Preferably, the motif is encoded by the V gene of K5B8 and the V gene of TR1.6. This humanized antibody preferably contains the variable region of a tat antibody.

Humanized antibody and uses thereof

Growing community of inventors

Houston, TX, United States of America

Abner Mhashilkar